Vimta Labs Q2 FY27: PAT ₹210 Cr & Rev ₹1,129 Cr

Investor Takeaways

Revenue grew 13.7% YoY to ₹1,129 Cr in Q1 FY27

Net Profit increased 11.4% YoY to ₹210 Cr

EBITDA rose 16% YoY to ₹411 Cr

Export revenue contributed ~40% of total revenue with strong U.S. traction

60% capacity utilization of 200,000 sq. ft. infrastructure

Management highlighted 90% customer retention and cross-selling from biologics integration

Capex of ₹80 Cr planned for FY27 including ₹10 Cr for Biologics CRADS

Operating margins expected to remain stable despite near-term softness in food testing

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,129 Cr	13.7%
Net Profit	₹210 Cr	11.4%
EBITDA	₹411 Cr	16%
EPS	[amount not verified]	11.4%
OPM	36.38%	13.7%

What Changed

Vimta Labs reported 13.7% YoY revenue growth to ₹1,129 Cr in Q1 FY27, with Net Profit up 11.4% to ₹210 Cr and EBITDA increasing 16% to ₹411 Cr. Export revenue accounted for approximately 40% of total revenue, driven by strong U.S. market traction. The company achieved 60% capacity utilization of its 200,000 sq. ft. infrastructure, supporting growth in pharma services and clinical research. Management emphasized 90% customer retention and cross-selling opportunities from biologics integration. Capex of ₹80 Cr is planned for FY27, including ₹10 Cr for Biologics CRADS. Operating margins are expected to remain stable despite near-term softness in food testing segments, with focus shifting to domestic market expansion to offset import-export challenges.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Vimta Labs	32.79	N/A	N/A	2,012.35
Sun Pharmaceutical	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals	80.06	N/A	N/A	1,49,108.91

Vimta Labs trades at a discount to Sun Pharmaceutical and Divi's Laboratories on P/E basis, with comparable scale but lower market capitalization.

Risks & Concerns

No specific risks identified in this filing

Near-term softness in food testing segments noted

Import-export challenges may impact international operations

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	89.92	21.5	36.79
Q2FY25	84.74	15.25	35.28
Q1FY25	81.76	12.28	30
Q4FY24	79.69	12.35	30.64

The company demonstrates consistent quarterly growth in revenue and profitability, with OPM expansion observed sequentially.

📄 View Original Announcement (PDF)

📊 Stock Analysis — VIMTALABS ✨ Ask AI About This

About Vimta Labs Limited (VIMTALABS)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹2,878.27 Cr P/E: 23.3 ROE: 19.2% ROCE: 24.3% Div Yield: 0.31%

View full VIMTALABS stock details →

📡 Get AI alerts when VIMTALABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track VIMTALABS — Free

💡 Ask AI about this filing

"What is the revenue contribution split between domestic and export markets?" "How will the INR80 crore capex specifically impact Biologics revenue growth?" "What is the expected timeline for achieving full capacity utilization?"

Ask AI Free →

📊 More VIMTALABS filings

See all VIMTALABS filings →

🔥 Also filed on 24 July 2026

CGPOWER CG Power and Industrial Solutions Limited Financial Results OMAXAUTO Omax Autos Limited Financial Results LENSKART Lenskart Solutions Limited Annual Report ALLDIGI Alldigi Tech Limited Financial Results NITCO Nitco Limited Corporate Action RKFORGE Ramkrishna Forgings Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIMTALABS files new disclosures

Track VIMTALABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.